Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
Alessandra TedeschiConstantine S TamRoger G OwenChristian BuskeVéronique LeblondMeletios DimopoulosMiriam SanteroJorge J CastilloJudith TrotmanSteven P TreonKeri YangBoxiong TangHeather AlleweltSheel PatelWai Y ChanAileen CohenShengnan ChenGisoo BarnesPublished in: Future oncology (London, England) (2024)
Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and EQ-5D-5L VAS scores. Results: Overall, 201 patients (102 zanubrutinib; 99 ibrutinib) were enrolled. Clinically meaningful differences were observed in diarrhea and nausea/vomiting in both the intent-to-treat population and in patients attaining very good partial response (VGPR) in earlier cycles of treatment, as well as in long-term physical functioning and fatigue in patients achieving VGPR. Conclusion: Treatment with zanubrutinib was associated with greater improvements in health-related quality of life compared with ibrutinib in patients with WM and MYD88 mutations. Clinical Trial Registration: NCT03053440 (ClinicalTrials.gov).